Dr. Marc Hedrick is the President and CEO at Plus Therapeutics, Inc. Previously, Dr. Hedrick served in a number of executive leadership roles including President, CEO, and Director at Cytori Therapeutics, Inc., and President and CEO of StemSource, Inc. Dr. Hedrick is a trained general, vascular, and plastic surgeon and former Associate Professor of Surgery and Pediatrics at the University of California, Los Angeles (UCLA). Dr. Hedrick also served as Co-Director of the Laboratory of Regenerative Bioengineering and Repair at UCLA.
Dr. Hedrick obtained his MD from the University of Texas Southwestern Medical School, Dallas and a MBA from The Anderson School at UCLA in 2005.
Andrew Sims is Vice President and Chief Financial Officer at Plus Therapeutics, Inc. Mr. Sims arrived at Plus Therapeutics having previously held Chief Financial Officer roles at several private equity-backed companies. His focus has been on mergers and acquisitions, integrations, corporate capitalization, and building out and managing teams to support global growth. Previously, Mr. Sims was Partner at Mazars, a global accounting, advisory, audit, tax and consulting firm. Working from both the Oxford, England and New York offices, Mr. Sims audited and advised global public clients, including a variety of healthcare companies, with average annual revenues in excess of $1 billion. Further, he was the lead partner on over 50 acquisitions ranging from $5 million to $4 billion in purchase price.
Mr. Sims is a native of the United Kingdom and is now a proud U.S. citizen. He is a Certified Public Accountant in the U.S. and a Chartered Accountant in England and Wales. He is a graduate of Buckingham University in the United Kingdom.
Norman LaFrance, MD is the Chief Medical Officer and Senior Vice President at Plus Therapeutics, Inc. He was previously Chief Medical Officer and Senior Vice President at Jubilant Pharma Ltd., responsible for all Pharma Medical & Regulatory Affairs activities.
Prior to Jubilant Pharma, Ltd., Dr. LaFrance served as Global Chief Medical Officer at IBA Molecular from 2010 to 2012, and as Senior Vice President, Clinical Development and Chief Medical Officer at Molecular Insight Pharmaceuticals from 2007 to 2010. Prior to industry, Dr. LaFrance practiced medicine and held academic faculty appointments at Johns Hopkins University School of Medicine in the departments of medicine and radiology and the Department of Radiological Sciences in the John Hopkins School of Hygiene and Public Health. He is Double Board Certified with Fellowship status both in internal medicine and nuclear medicine, maintains active medical licensure in the U.S. along with active, professional society membership.
Dr. LaFrance received his Bachelor of Science and Master of Engineering degrees in nuclear engineering and science from Rensselaer Polytechnic Institute, and his medial degree from the University of Arizona, College of Medicine, Tucson.
Russ Havranek is the Vice President of Corporate Strategy and New Product Planning at Plus Therapeutics, Inc. He was previously Vice President of Global Marketing and Business Development at Cytori Therapeutics.
Mr. Havranek has over 26 years of leadership experience developing and commercializing diagnostic and therapeutic products at global, publicly traded, biopharma and medical device companies. His prior roles in marketing, strategy, business development, general management, and R&D focused on the oncology, rare disease, cardiology, and orthopedic markets. These roles were held at Johnson & Johnson, Guidant (now Abbott), Genentech (now Roche), DJO Global (now Enovis), Volcano (now Philips), and CareFusion (now Becton Dickinson).
Mr. Havranek received a MBA in Marketing from the Haas School of Business at the University of California, Berkeley, a MS in Bioengineering from Clemson University, and a BS in Biomedical Engineering from Northwestern University.
Melissa Moore, PhD is the Vice President of Clinical Research at Plus Therapeutics, Inc.
Dr. Moore has over fifteen years of experience in oncology, molecular diagnostics and radiotherapeutic drug development. Her corporate roles include start-up leadership experience, full lifecycle product development, funding & capitalization, manufacturing and regulatory strategy. Prior to joining Plus Therapeutics, she was a co-founder of SOFIE and served as its Chief Technology Officer. While at Sofie, she was specifically responsible for leading the Clinical Development Program, Radiopharmaceutical Contract Manufacturing Operations, and the Quality Assurance/Regulatory Affairs Division. Dr. Moore has also led Development at the Damon Runyon Cancer Research Foundation in New York.
Previously, she was a Visiting Scientist at University of California, Los Angeles and principal investigator on numerous governmental grants and contracts. Additionally, she sits on various related scientific review boards for the National Institute of Health. Dr. Moore received her Bachelor of Science degree from University of California, Berkeley and her PhD from University of California, Los Angeles, where she also completed her post-doctorate research in Molecular and Medical Pharmacology.
Pius Maliakal, M. Pharm., Ph.D. is the Vice President of Clinical Operations at Plus Therapeutics, Inc. and is responsible for the strategy and planning of key clinical operational initiatives, focusing on advancing the Company’s lead clinical trials, ReSPECT-GBM and ReSPECT-LM, and further developing the broader pipeline.
Dr. Maliakal is an accomplished R&D professional who brings over 20 years of global and domestic experience to Plus Therapeutics. Prior to joining the Company, he served as Director of Clinical Science at PTC Therapeutics, leading the clinical development, clinical trial operations, strategies, and data interpretations of all oncology assets across the enterprise. Previously, as Director of Clinical Development at Eagle Therapeutics, he led and facilitated the core design and conduct of Phase 1 and 2 clinical trials within breast cancer, lung cancer and other solid tumors. During his prior tenure at Immunomedics, he was instrumental in the Phase 1 through Phase 3 clinical trials of Trodelvy (sacituzumab govitecan) leading to accelerated FDA approval for treatment of triple-negative breast cancer as well as other investigational agents, including unesbulin and emvododstat.
Dr. Maliakal earned his M. Pharm. from Nagpur University, India and his Ph.D. from the University of Otago, New Zealand.